BioNTech (NASDAQ:BNTX) Receives Buy Rating from Jefferies Financial Group

Jefferies Financial Group restated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a report published on Wednesday morning,MarketScreener reports.

Several other equities analysts have also recently issued reports on the stock. TD Cowen lowered their target price on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Wednesday, March 11th. Finally, Truist Financial set a $155.00 target price on shares of BioNTech in a research report on Tuesday, March 10th. Thirteen equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Trading Up 2.3%

BioNTech stock opened at $88.77 on Wednesday. BioNTech has a one year low of $79.52 and a one year high of $124.00. The business’s fifty day moving average is $104.54 and its 200 day moving average is $101.82. The stock has a market capitalization of $21.30 billion, a PE ratio of -16.94 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently made changes to their positions in BNTX. Dodge & Cox grew its position in BioNTech by 315.7% during the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after buying an additional 2,769,654 shares during the period. BNP Paribas Financial Markets raised its position in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the period. GSK plc purchased a new position in shares of BioNTech during the 4th quarter worth $84,711,000. Invesco Ltd. boosted its stake in shares of BioNTech by 5.6% during the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock worth $72,517,000 after acquiring an additional 35,958 shares during the last quarter. Finally, Morgan Stanley grew its position in shares of BioNTech by 12.9% during the 4th quarter. Morgan Stanley now owns 680,669 shares of the company’s stock valued at $64,800,000 after acquiring an additional 77,653 shares during the period. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.